Problems in salmonellosis: rationale for clinical trials with newer beta-lactam agents and quinolones.
Disease syndromes caused by Salmonella species continue to be important, as evidenced by a major outbreak of infection due to multiresistant Salmonella typhimurium in 1985; this outbreak involved more than 12,000 people in five north-central states of the United States. Salmonella species have become progressively more resistant in recent years to the clinically useful antibiotics (trimethoprim-sulfamethoxazole, ampicillin, and chloramphenicol). The clinical experience accumulated thus far indicates that two new classes of antimicrobial agents, the third-generation cephalosporins and the quinolones, offer significant potential for the treatment of specific problems in salmonellosis: bacteremia and enteric fever, meningitis, osteomyelitis, and the chronic carrier state.
D000667:Ampicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D002353:Carrier State / Q000188:drug therapy; D002511:Cephalosporins / Q000627:therapeutic use*; D002701:Chloramphenicol / Q000627:therapeutic use; D002763:Cholecystectomy; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D004338:Drug Combinations / Q000627:therapeutic use; D006801:Humans; D008581:Meningitis / Q000188:drug therapy; D008826:Microbial Sensitivity Tests; D010019:Osteomyelitis / Q000188:drug therapy; D010403:Penicillin Resistance; D011804:Quinolines / Q000627:therapeutic use*; D012480:Salmonella Infections / Q000188:drug therapy*; D018805:Sepsis / Q000188:drug therapy; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014435:Typhoid Fever / Q000188:drug therapy
D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D011804:Quinolines; D002701:Chloramphenicol; D000667:Ampicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole